Innovaxis, a novel company for “custom medicine”

Innovaxis is the first Enterprise that commercialises advances therapies and tissue regeneration integrating High Throughput Screening (HTS) services.

Innovaxis, a R&D based-company located in the Parque Científico Tecnológico of Jerez (Cádiz, Spain), is devoted to the development and commercialisation of advanced cellular therapies. The Innovaxis technology is currently undergoing a clinical trial – phase II. Its milestone is the in vitro culture and management of cells as a “pharmaceutical product”. The treatments are utterly adapted to each and every patient, since the patient themselves are their own donor. Their cells are managed and subsequently administered to the same patient, hence avoiding any immunologic incompatibility.

At the same time, Innovaxis has developed the technology required to obtain adult stem cells from bone marrow and adipose tissue, as well as to culture them in vitro, specifically designed to maintain their functionality and subsequent pharmaceutical-making for the administration in advanced therapies in the treatment of several cardiovascular diseases.

Innovaxis offers:

  • CRO services
  • CMO services to produce cells for advanced therapies
  • The sale of “cellular medicines” as advanced therapies

The target for the sale of all these products and services is the international market: EU, USA, Canada, Japan and Australia, mainly.
The target clients are the domestic and international pharmaceutical companies, as well as the national health service of western countries.

The peculiarity of Innovaxis is the flexibility and the extent of the standing of a research based-company in the context of an expanding and innovative field.

For further information please contact:
Paula Esteban del Río.
Communication and Marketing Department
Móvil: +34 609 834 996

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

More articles

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice